You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: 100ABSTRACTTechnology to deliveron demandmolecules that bind targets or catalyze reactions of choice has been a goal of chemistry foryearsEven todaytheory is inadequate to support de novo design of receptors having useful affinity or catalysts having useful turnoverThusmany have sought to create those catalysts on a DNA or RNAcollectivelyxNAusing the Darwinism to these biomolecules to evolveunder lab ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
ErythroMer Nanoscale Bio Synthetic Red Cell Substitute
SBC: KaloCyte Inc Topic: NHLBIPROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents
SBC: BIOVENTURES, INC Topic: 172Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type Diabetes
SBC: ONEVAX, LLC Topic: NIAIDType Diabetes T D results from a breakdown of self tolerance that is characterized by immune cell mediated destruction of the insulin producing cells in the pancreas Ultimately glucose metabolism is interrupted resulting in the development of life threatening complications such as heart disease and renal failure T D affects an estimated million Americans with more than new patie ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Probabilistic Modeling for Software Guided Radiotherapy Patient Plan QA
SBC: SUN NUCLEAR CORP. Topic: 103Errors in the planning and delivery of radiation therapy can result in inferior outcomes for patients The magnitude of this problem is now well appreciated from cooperative group trials and other sources At present however there are few concrete tools to reduce the chance of plan errors passing undetected Current practice uses a variety of error mitigation means such as human inspection of th ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Identification of Small Molecule Amyloid Beta Peptide Reducing Agent
SBC: Smart Biomolecules, Inc. Topic: NIAAlzheimer s disease AD is a multifactorial heterogeneous and enormously complex disorder characterized by progressive intellectual deterioration Although remarkable advances have been made in unraveling the biological basis of the disease in the last two decades that immense knowledge has not been translated in to successful therapy With the failure of secretase inhibitors at the clinical tr ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Develop a new cisplatin based drug combination with reduced ototoxicity
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side effects have been associated with the use of cisplatin such as bilateral and irreversible hearing loss In the cochlea cisplatin can trigger the production of reactive oxygen species and activate sev ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nutraceutical Product against Noise Induce Hearing Loss
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARY The most common occupational and environmental hazard in this country is noise Itandapos s not surprising then that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit behind only age related hearing loss presbycusis Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no effe ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing a novel therapy for diabetic retinopathy
SBC: EVERGLADES BIOPHARMA LLC Topic: WProject Summary Diabetic retinopathy DR is a leading cause of vision loss affecting about million people worldwide A major breakthrough in DR therapy is the recent approval of vascular endothelial growth factor VEGF inhibitors However anti VEGF therapy has limited efficacy with a number of side effects The critical barrier is how to identify other angiogenic targets for alternative or ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health